BioGenes GmbH, a biotechnology company based in Berlin, Germany, specializing in antibody development, has been chosen as a partner of the EU funded research project cNEUPRO. cNEUPRO stands for Clinical Neuroproteomics of Neurodegenerative Diseases and unites nineteen biotech and bioinformatics’ companies as well as leading clinical and proteomic dementia research centers. The project will analyze neurodegenerative diseases and discover novel biomarkers and thus improve early diagnosis of Alzheimer"s dementia.